Subscribe
ftc
parbradyphoto / iStockphoto.com
11 July 2018Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

The US Federal Trade Commission (FTC) has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Impax to divest 10 products amid acquisition by Amneal
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
Amneal and Impax merge to become ‘fifth largest’ generics company
19 October 2017   Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Impax to divest 10 products amid acquisition by Amneal
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
Amneal and Impax merge to become ‘fifth largest’ generics company
19 October 2017   Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Impax to divest 10 products amid acquisition by Amneal
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
Amneal and Impax merge to become ‘fifth largest’ generics company
19 October 2017   Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler